Ocular Therapeutix (OCUL) EBT Margin (2014 - 2026)
Ocular Therapeutix (OCUL) recorded quarterly EBT Margin of 835.11% in Q1 2026, down 69.59% quarter-over-quarter from 492.45% in Q4 2025, and down 24552.0% on a YoY basis from N/an in Q1 2025.
Ocular Therapeutix (OCUL) EBT Margin (2014 - 2026) Analysis & Trends
Ocular Therapeutix's EBT Margin history runs 13 years deep, the most recent figure standing at 835.11% for Q1 2026.
- In Q1 2026, EBT Margin fell 24552.0% year-over-year to 835.11%; the TTM figure through Mar 2026 stood at 558.22% (down 22894.0% YoY), while the FY2025 annual figure was 507.2%, down 24815.0% from the prior year.
- EBT Margin was 835.11% for Q1 2026 at Ocular Therapeutix, down from 492.45% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 142.09% in Q3 2023 to a low of 835.11% in Q1 2026.
- Historically, EBT Margin has averaged 305.69% across 5 years, with a median of 214.88% in 2024.
- The sharpest annual moves came in 2022 and 2025: EBT Margin surged 15036 bps in 2022, then sank 37472 bps in 2025.
- A 5-year view of EBT Margin shows it stood at 147.67% in 2022, then declined by 4 bps to 153.65% in 2023, then plunged by 87 bps to 286.92% in 2024, then tumbled by 72 bps to 492.45% in 2025, then slumped by 70 bps to 835.11% in 2026.
- The last three EBT Margin figures came in at 835.11% (Q1 2026), 492.45% (Q4 2025), and 467.35% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ocular Therapeutix | 2.12 Bn | 2.12 Bn | 9.46 Mn | -835.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -835.11% |
| Dec 31, 2025 | -492.45% |
| Sep 30, 2025 | -467.35% |
| Jun 30, 2025 | -499.31% |
| Mar 31, 2025 | -589.60% |
| Dec 31, 2024 | -286.92% |
| Sep 30, 2024 | -282.46% |
| Jun 30, 2024 | -247.86% |
| Mar 31, 2024 | -214.88% |
| Dec 31, 2023 | -153.65% |
| Sep 30, 2023 | -142.09% |
| Jun 30, 2023 | -143.64% |
| Mar 31, 2023 | -177.61% |
| Dec 31, 2022 | -147.67% |
| Sep 30, 2022 | -192.70% |
| Jun 30, 2022 | -175.60% |
| Mar 31, 2022 | -147.86% |
| Dec 31, 2021 | -160.25% |
| Sep 30, 2021 | -174.28% |
| Jun 30, 2021 | -186.70% |